← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 6, 2012Last known activity
Nov 30, 2024
Defunct as of Jul 1, 2018
Timeline
1990s
- Jun 1, 1998
Vasgene Therapeutics, Inc— Founded
2010s
- Jul 1, 2018
Vasgene Therapeutics, Inc— Defunct
Drugs by trial phase (11 distinct, 9 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cholangiocarcinoma
- Disease Progression
- Gallbladder Neoplasms
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Pancreatic Neoplasms
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Sarcoma
- Sarcoma, Kaposi
- Squamous Cell Carcinoma of Head and Neck
Recent trials (9)
- NCT06493552Lead sponsorPhase 2/Phase 3Nov 30, 2024
- NCT04486781Lead sponsorPhase 2Dec 31, 2020
- NCT04091867CollaboratorPhase 1Oct 31, 2019
- NCT04033432CollaboratorPhase 2Sep 3, 2019
- NCT03993106Lead sponsorPhase 2Jul 31, 2019
- NCT03519984CollaboratorPhase 1May 9, 2018
- NCT02799485CollaboratorPhase 2Nov 1, 2015
- NCT02495896CollaboratorPhase 1Sep 1, 2015
- NCT01642342CollaboratorPhase 1Sep 6, 2012
Details
- Founded
- Los Angeles, CA, US Jun 1, 1998
- Last known activity
- Nov 30, 2024